Alteration of the Intrinsic Apoptosis Pathway Is Involved in Notch-induced Chemoresistance to Gemcitabine in Pancreatic Cancer

Archives of Medical Research

Volumn 45, Issue 1, 2014, Pages 15-20

  Du, Xiao ^a   Zhao, Yu pei ^a,b   Zhang, Tai ping ^a   Zhou, Li ^a   Chen, Ge ^a   Wang, Tian xiao ^a   You, Lei ^a   Shu, Hong ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Chemoresistance; Gemcitabine; Intrinsic apoptosis pathway; Notch; Pancreatic cancer

Indexed keywords

CASPASE 3; DAPT; GAMMA SECRETASE INHIBITOR; GEMCITABINE; NOTCH RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PANCREAS CANCER; PROTEIN EXPRESSION; TRANSIENT TRANSFECTION;

CHEMORESISTANCE; GEMCITABINE; INTRINSIC APOPTOSIS PATHWAY; NOTCH; PANCREATIC CANCER;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HUMANS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84892559940     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.10.001     Document Type: Article

References (37)

1. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Shrikhande S.V., Kleeff J., Reiser C., et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol 2007, 14:118-127.
3. Gillen S., Schuster T., Meyer Zum Büschenfelde C., et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010, 7:e1000267.
4. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605-1617.
5. Xie D.R., Yang Q., Chen D.L., et al. Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival. Jpn J Clin Oncol 2010, 40:432-441.
6. Long J., Zhang Y., Yu X., et al. Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 2011, 15:817-828.
7. Miyamoto Y., Maitra A., Ghosh B., et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003, 3:565-576.
8. Büchler P., Gazdhar A., Schubert M., et al. The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg 2005, 242:791-800.
9. Wang Z., Banerjee S., Li Y., et al. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006, 66:2778-2784.
10. Wang Z., Zhang Y., Li Y., et al. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 2006, 5:483-493.
11. Kimura K., Satoh K., Kanno A., et al. Activation of Notch signaling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice. Cancer Sci 2007, 98:155-162.
12. De La O.J.P., Emerson L.L., Goodman J.L., et al. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci USA 2008, 105:18907-18912.
13. Mullendore M.E., Koorstra J.B., Li Y.M., et al. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res 2009, 15:2291-2301.
14. Ristorcelli E., Beraud E., Mathieu S., et al. Essential role of Notch signaling in apoptosis of human pancreatic tumoral cells mediated by exosomal nanoparticles. Int J Cancer 2009, 125:1016-1026.
15. Bao B., Wang Z., Ali S., et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 2011, 307:26-36.
16. Yao J., Qian C. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway. Med Oncol 2010, 27:1017-1022.
17. Güngör C., Zander H., Effenberger K.E., et al. Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res 2011, 71:5009-5019.
18. Tasaka T., Akiyoshi T., Yamaguchi K., et al. Gamma-secretase complexes regulate the responses of human pancreatic ductal adenocarcinoma cells to taxanes. Anticancer Res 2010, 30:4999-5010.
19. Cook N., Frese K.K., Bapiro T.E., et al. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med 2012, 209:437-444.
20. Mizuma M., Rasheed Z.A., Yabuuchi S., et al. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Mol Cancer Ther 2012, 11:1999-2009.
21. Ranganathan P., Weaver K.L., Capobianco A.J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 2011, 11:338-351.
22. Wang Z., Li Y., Ahmad A., et al. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta 2010, 1806:258-267.
23. Murata J., Ohtsuka T., Tokunaga A., et al. Notch-Hes1 pathway contributes to the cochlear prosensory formation potentially through the transcriptional down-regulation of p27Kip1. J Neurosci Res 2009, 87:3521-3534.
24. Nakamura T., Tsuchiya K., Watanabe M. Crosstalk between Wnt and Notch signaling in intestinal epithelial cell fate decision. J Gastroenterol 2007, 42:705-710.
25. Fu Y., Chang A., Chang L., et al. Differential regulation of transforming growth factor β signaling pathways by Notch in human endothelial cells. J Biol Chem 2009, 284:19452-19462.
26. Leong K.G., Niessen K., Kulic I., et al. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med 2007, 204:2935-2948.
27. Kuramitsu Y., Wang Y., Taba K., et al. Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells. Anticancer Res 2012, 32:2295-2299.
28. Giovannetti E., Toffalorio F., De Pas T., et al. Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?. Pharmacogenomics 2012, 13:1073-1086.
29. Wang Z., Li Y., Ahmad A., et al. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 2011, 8:27-33.
30. Sheikh R., Walsh N., Clynes M., et al. Challenges of drug resistance in the management of pancreatic cancer. Expert Rev Anticancer Ther 2010, 10:1647-1661.
31. Schniewind B., Christgen M., Kurdow R., et al. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer 2004, 109:182-188.
32. Stylianou S., Clarke R.B., Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res 2006, 66:1517-1525.
33. Sprick M.R., Walczak H. The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim Biophys Acta 2004, 1644:125-132.
34. Adams J.M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337.
35. Zhou Y.A., Zhang T., Zhao J.B., et al. The adenovirus-mediated transfer of PTEN inhibits the growth of esophageal cancer cells invitro and invivo. Biosci Biotechnol Biochem 2010, 74:736-740.
36. Lu H.F., Chie Y.J., Yang M.S., et al. Apigenin induces caspase-dependent apoptosis in human lung cancer A549 cells through Bax- and Bcl-2-triggered mitochondrial pathway. Int J Oncol 2010, 36:1477-1484.
37. Hong L., Han Y., Zhang H., et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010, 251:1056-1063.